{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:52:33Z","timestamp":1779173553775,"version":"3.51.4"},"reference-count":28,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Purpose\/Objective(s): Peritoneal carcinosis can occur in several gastrointestinal or gynecological malignancies and its prognosis is usually poor. With the advent of more effective systemic agents, the overall survival of metastatic patients has been revolutionized and isolated peritoneal or abdominal wall metastases might benefit from local treatments; Stereotactic Body Radiotherapy (SBRT) might be considered in selected patients with oligometastatic presentation. Materials\/Methods: Oligometastases were defined according to recent ESTRO\/EORTC consensus. Inclusion criteria were as follows: ECOG PS \u2264 2, written informed consent, up to five lesions to be treated at the same time, patients treated with radiotherapy schedules applying minimum 6 Gy per fraction. The primary endpoint of the study was local control (LC); acute and late toxicity, distant progression-free survival (DPFS), time-to-next systemic treatment (TNST), polymetastatic-free survival (PMFS) and overall survival (OS) were secondary endpoints. Toxicity was assessed according to CTCAE criteria v5.0. Statistical associations between clinical variables and outcomes were assessed using Fisher\u2019s exact test, and Kruskal\u2013Wallis test, as appropriate. Survival outcomes were estimated using the Kaplan\u2013Meier method and compared using the log-rank test. Results: Between April 2020 and September 2024 a total of 26 oligometastatic lesions located in the peritoneum or in the abdominal wall detected in 20 patients received SBRT with Helical Tomotherapy. All cases have been assessed by a multidisciplinary team. Only in three patients out of twenty did more than one lesion receive SBRT: two lesions in two patients, and five lesions in a single case of colorectal cancer with ongoing third-line systemic treatment. Median total dose was 30 Gy (27\u201335 Gy) in five fractions (3\u20135). The most frequent primary neoplasm was ovarian cancer in 14\/20, endometrial in 2\/20, while the remaining were colorectal, vaginal, pancreatic and non-small cell lung cancer. Four lesions were located in the abdominal wall, while the remaining twenty-two were located in the peritoneum. Concurrent systemic therapy was administered in 18\/20 patients. With a median follow-up of 15 months (range, 6\u201359), our 1-year LC was 100%, while 1-year DPFS, PMFS, TNTS and OS rates were 54%, 69%, 61% and 83%, respectively. Abdominal wall location and treatment of a subsequent oligometastatic recurrence with a second course of SBRT were both significantly associated with improved OS (p = 0.03 and p = 0.04, respectively). No G \u2265 3 adverse events occurred. Conclusion: Our preliminary data support the use of SBRT in selected cases of oligometastatic disease located in the peritoneum or in the abdominal wall with excellent results in terms of tolerability and promising clinical outcomes.<\/jats:p>","DOI":"10.3390\/jpm15070312","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T09:56:54Z","timestamp":1752487014000},"page":"312","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stereotactic Body Radiotherapy for the Treatment of Oligometastases Located in the Peritoneum or in the Abdominal Wall: Preliminary Results from a Mono-Institutional Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0390-9511","authenticated-orcid":false,"given":"Francesco","family":"Cuccia","sequence":"first","affiliation":[{"name":"Radiation Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8144-0168","authenticated-orcid":false,"given":"Salvatore","family":"D\u2019Alessandro","sequence":"additional","affiliation":[{"name":"Radiation Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7899-4308","authenticated-orcid":false,"given":"Marina","family":"Campione","sequence":"additional","affiliation":[{"name":"Clinical Research, ARNAS Civico Hospital, 90100 Palermo, Italy"},{"name":"Department of Biostatistics, Kore University, 94100 Enna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Figlia","sequence":"additional","affiliation":[{"name":"Radiation Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Mortellaro","sequence":"additional","affiliation":[{"name":"Radiation Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Spera","sequence":"additional","affiliation":[{"name":"Radiation Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Music\u00f2","sequence":"additional","affiliation":[{"name":"Gynecology Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Abbate","sequence":"additional","affiliation":[{"name":"Gynecology Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Russo","sequence":"additional","affiliation":[{"name":"Medical Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-1419","authenticated-orcid":false,"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[{"name":"Medical Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-1436","authenticated-orcid":false,"given":"Giuseppe","family":"Carruba","sequence":"additional","affiliation":[{"name":"Clinical Research, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livio","family":"Blasi","sequence":"additional","affiliation":[{"name":"Medical Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Ferrera","sequence":"additional","affiliation":[{"name":"Radiation Oncology, ARNAS Civico Hospital, 90100 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0035-1564431","article-title":"Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy","volume":"28","author":"Nadler","year":"2015","journal-title":"Clin. Colon. Rectal Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1369\/0022155417742897","article-title":"Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review","volume":"66","author":"Nieuwland","year":"2018","journal-title":"J. Histochem. Cytochem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.semcancer.2021.02.009","article-title":"The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community","volume":"77","author":"Petrillo","year":"2021","journal-title":"Semin Cancer Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20180841","DOI":"10.1259\/bjr.20180841","article-title":"Pelvic side wall recurrence in locally advanced cervical carcinoma treated with definitive chemoradiation-clinical impact of pelvic wall dose","volume":"92","author":"Gangopadhyay","year":"2019","journal-title":"Br. J. Radiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Breusa, S., Zilio, S., Catania, G., Bakrin, N., Kryza, D., and Lollo, G. (2023). Localized chemotherapy approaches and advanced drug delivery strategies: A step forward in the treatment of peritoneal carcinomatosis from ovarian cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1125868"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"van Oudheusden, T.R., Razenberg, L.G., van Gestel, Y.R., Creemers, G.J., Lemmens, V.E., and de Hingh, I.H. (2015). Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin. Sci. Rep., 5.","DOI":"10.1038\/srep18632"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","article-title":"Mirvetuximab soravtansine-gynx: First antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer","volume":"34","author":"Bogani","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104063","DOI":"10.1016\/j.critrevonc.2023.104063","article-title":"Advances in immunotherapy for gynecological malignancies","volume":"188","author":"Tu","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1085","DOI":"10.1002\/onco.13747","article-title":"Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer","volume":"26","author":"Loi","year":"2021","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(21)00233-6","article-title":"Contemporary radiotherapy: Present and future","volume":"398","author":"Chandra","year":"2021","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.soc.2023.02.004","article-title":"The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer","volume":"32","author":"Tam","year":"2023","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bauman, G.S., Corkum, M.T., Fakir, H., Nguyen, T.K., and Palma, D.A. (2021). Ablative radiation therapy to restrain everything safely treatable (ARREST): Study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08020-2"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Palma, D.A., Olson, R., Harrow, S., Correa, R.J.M., Schneiders, F., Haasbeek, C.J.A., Rodrigues, G.B., Lock, M., Yaremko, B.P., and Bauman, G.S. (2019). Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial. BMC Cancer., 19.","DOI":"10.1186\/s12885-019-5977-6"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.hrthm.2024.07.029","article-title":"Stereotactic arrhythmia radioablation (STAR)-A systematic review and meta-analysis of prospective trials on behalf of the STOPSTORM.eu consortium","volume":"22","author":"Miszczyk","year":"2025","journal-title":"Heart Rhythm"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Franzetti, J., Volpe, S., Catto, V., Conte, E., Piccolo, C., Pepa, M., Piperno, G., Camarda, A.M., Cattani, F., and Andreini, D. (2022). Stereotactic Radiotherapy Ablation and Atrial Fibrillation: Technical Issues and Clinical Expectations Derived From a Systematic Review. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.849201"},{"key":"ref_21","first-page":"449","article-title":"The role of radiotherapy in the treatment of peritoneal carcinomatosis","volume":"134","author":"Boterberg","year":"2007","journal-title":"Cancer Treat Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Boldrini, L., Romano, A., Placidi, L., Mattiucci, G.C., Chiloiro, G., Cusumano, D., Pollutri, V., Antonelli, M.V., Indovina, L., and Gambacorta, M.A. (2020). Case Report: First in Human Online Adaptive MR Guided SBRT of Peritoneal Carcinomatosis Nodules: A New Therapeutic Approach for the Oligo-Metastatic Patient. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.601739"},{"key":"ref_23","first-page":"189","article-title":"Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experience","volume":"7","author":"Smile","year":"2021","journal-title":"J. Radiosurg SBRT."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Nicosia, L., Trapani, G., Rigo, M., Giaj-Levra, N., Mazzola, R., Pastorello, E., Ricchetti, F., Cuccia, F., Figlia, V., and Fiorini, M. (2022). 1.5 T MR-Guided Daily Adapted SBRT on Lymph Node Oligometastases from Prostate Cancer. J. Clin. Med., 11.","DOI":"10.20944\/preprints202210.0205.v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10585-025-10354-1","article-title":"MRI-guided stereotactic radiotherapy for oligometastatic peritoneal carcinomatosis: Toward integrative oncologic approaches","volume":"42","author":"Romano","year":"2025","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00432-021-03739-8","article-title":"Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases","volume":"147","author":"Cuccia","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ijgc-2024-005361","article-title":"Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)","volume":"34","author":"Durante","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.clon.2023.07.011","article-title":"Stereotactic Body Reirradiation in Gynaecological Cancer: Outcomes and Toxicities from a Single Institution Experience","volume":"35","author":"Macchia","year":"2023","journal-title":"Clin. Oncol. (R Coll. Radiol.)"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/7\/312\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:09:28Z","timestamp":1760033368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/7\/312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jpm15070312"],"URL":"https:\/\/doi.org\/10.3390\/jpm15070312","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}